- Home
- IMKTA vs DAWN Comparison
IMKTA vs DAWN Comparison
Compare IMKTA & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMKTA
- DAWN
- Stock Information
- Founded
- IMKTA 1963
- DAWN 2018
- Country
- IMKTA United States
- DAWN United States
- Employees
- IMKTA N/A
- DAWN N/A
- Industry
- IMKTA Food Chains
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- IMKTA Consumer Staples
- DAWN Health Care
- Exchange
- IMKTA Nasdaq
- DAWN Nasdaq
- Market Cap
- IMKTA 1.2B
- DAWN 1.2B
- IPO Year
- IMKTA N/A
- DAWN 2021
- Fundamental
- Price
- IMKTA $65.64
- DAWN $7.97
- Analyst Decision
- IMKTA
- DAWN Strong Buy
- Analyst Count
- IMKTA 0
- DAWN 7
- Target Price
- IMKTA N/A
- DAWN $32.29
- AVG Volume (30 Days)
- IMKTA 107.4K
- DAWN 1.1M
- Earning Date
- IMKTA 05-08-2025
- DAWN 05-05-2025
- Dividend Yield
- IMKTA 1.01%
- DAWN N/A
- EPS Growth
- IMKTA N/A
- DAWN N/A
- EPS
- IMKTA 4.15
- DAWN N/A
- Revenue
- IMKTA $5,446,662,271.00
- DAWN $131,161,000.00
- Revenue This Year
- IMKTA N/A
- DAWN $26.74
- Revenue Next Year
- IMKTA N/A
- DAWN $68.48
- P/E Ratio
- IMKTA $15.72
- DAWN N/A
- Revenue Growth
- IMKTA N/A
- DAWN N/A
- 52 Week Low
- IMKTA $58.92
- DAWN $7.52
- 52 Week High
- IMKTA $82.01
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- IMKTA 60.88
- DAWN 38.02
- Support Level
- IMKTA $62.59
- DAWN $7.52
- Resistance Level
- IMKTA $65.19
- DAWN $8.29
- Average True Range (ATR)
- IMKTA 1.55
- DAWN 0.43
- MACD
- IMKTA 0.50
- DAWN 0.08
- Stochastic Oscillator
- IMKTA 94.52
- DAWN 33.09
About IMKTA Ingles Markets Incorporated
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.